Nuovo Biologics is commercializing an innovative platform of protein drugs which could have profound implications for human and animal health. Two products are currently under development, PVX – an antiviral, and MMX – an antitumor formulation.
Nuovo Biologics has been awarded a ‘Minor Use’ designation by the FDA for canine malignant melanoma to pursue a Conditional New Animal Drug Application (CNADA). The Minor Use Designation Approval is published on the FDA/CVM website. click here (scroll to number 96) .